ORIGINAL RESEARCH article
Front. Med.
Sec. Hematology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1682909
This article is part of the Research TopicNew frontiers in safeguarding blood component transfusions: Innovative approaches to bacterial risk reductionView all articles
Ultrastructure of human platelet concentrates after treatment with pathogen reduction technologies for prolonged storage
Provisionally accepted- 1Department II of Anatomy, University of Cologne and University Hospital of Cologne, 50937 Cologne, Germany, Cologne, Germany
- 2Universitat zu Koln Institut II fur Anatomie, Cologne, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background and Objectives: Pathogen reduction technologies (PRTs) increase blood supply safety but may also increase platelet storage lesion, probably due to mitochondrial DNA damage. The purpose of this study was to investigate whether these changes are morphologically detectable. Materials and Methods: Blood platelets were obtained by triple-dose apheresis collection (n=8). Immediately after splitting, single units were left untreated (CONTROL) or treated with either psoralen-UVA (INTERCEPT) or riboflavin-UVB (MIRASOL). All platelet units were resuspended in platelet additive solution (INTERSOL or SSP+) and stored for up to seven days. Seven samples from each donation were examined by electron microscopy fresh, i.e. immediately after collection, and after1 day and 7 days of storage either untreated or treated with INTERCEPT or MIRASOL PRT. The volumes of mitochondria and of the canalicular system (CS) were measured. Results: Freshly isolated platelets (0 days storage) contained 2.4% mitochondria (volume density) and 4.5% CS (volume density). After 1 day of storage mitochondrial volume density was reduced to 1.5% in untreated, 1.3% in INTERCEPT-treated and 1.6% in MIRASOL-treated platelet concentrates, i.e. a loss of up to 37% of mitochondrial volume regardless of treatment. After 7 days storage mitochondrial volume density was 1.3%, 1.3% and 1.5% respectively; neither at 1 nor at 7 days storage were any noteworthy differences between untreated, INTERCEPT or MIRASOL-treated platelets. In stark contrast to mitochondria the CS ballooned up to 88% in all groups. After 1 day of storage CS volume density was increased to 8.6% in untreated, 8.4% in INTERCEPT-treated and 7.0% in MIRASOL-treated platelet concentrates. After 7 days storage CS volume density was 8.0%, 8.3% and 6.3% respectively; neither at 1 nor at 7 days storage were significant differences between untreated, INTERCEPT or MIRASOL-treated platelets. Only at 7 days a slight tendency of a smaller CS in MIRASOL versus INTERCEPT and untreated CONTROL groups was observed. Conclusion: Platelet mitochondrial volume shrinks and canalicular system swells within the first 24h after collection and then both remain rather constant for up to seven days with or without PRT treatment. Pathogen reduction technology – both INTERCEPT and MIRASOL – does not increase morphological platelet storage lesion.
Keywords: blood system, Intercept, MIRASOL-PRT, Mitochondria, canalicularsystem, pathogen-reduction technology
Received: 09 Aug 2025; Accepted: 25 Sep 2025.
Copyright: © 2025 Barham. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mohammed Shuwkut Barham, barham.mohammed@uk-koeln.de
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.